Daniel A. Holterman, Ph.D.

Affiliations: 
2003 Old Dominion University, Norfolk, VA, United States 
Area:
Immunology, Oncology
Google:
"Daniel Holterman"
Mean distance: 35622
 

Parents

Sign in to add mentor
Richard P. Ciavarra grad student 2003 Old Dominion University
 (Characterization of mouse prostate tumor -infiltrating leukocytes.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Gatalica Z, Snyder C, Maney T, et al. (2014) Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2965-70
Gatalica Z, Snyder CL, Yeatts K, et al. (2014) Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status. Journal of Clinical Oncology. 32: 3625-3625
Smith SE, Holterman DA, Brown KM, et al. (2012) Abstract 3607: Differential protein expression and miR content of sorted subsets of circulating microvesicles from cancer patients and healthy controls Cancer Research. 72: 3607-3607
Deng T, Spetzler DB, Holterman D, et al. (2011) Abstract 444: Subpopulations of circulating microvesicles have different microRNA profiles Cancer Research. 71: 444-444
Spetzler DB, Deng T, Tinder T, et al. (2011) Abstract 4060: Enriching for rrare subpopulations of circulating microvesicles by the depletion of endothelial- and leukocyte-derived microvesicles Cancer Research. 71: 4060-4060
Holterman DA, Duncan JE, Deng T, et al. (2011) Abstract 1568: Plasma-derived circulating microvesicles can both detect and help monitor breast cancer-related pathologies Cancer Research. 71: 1568-1568
Holterman DA, Diaz JI, Blackmore PF, et al. (2006) Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urologic Oncology. 24: 97-108
Ciavarra RP, Holterman DA, Brown RR, et al. (2004) Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 13-26
Ciavarra RP, Brown RR, Holterman DA, et al. (2003) Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunology, Immunotherapy : Cii. 52: 535-45
Somers KD, Brown RR, Holterman DA, et al. (2003) Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. International Journal of Cancer. Journal International Du Cancer. 107: 773-80
See more...